Apreo Health Announces First Patient Treated in BREATHE-3, Pivotal Clinical Trial of Company’s BREATHE Airway Scaffold
MENLO PARK, Calif.--(BUSINESS WIRE)--Apreo Health, a clinical-stage medical device company pioneering a novel, tissue-sparing approach for treating severe emphysema, today announced that the first ...
What is the anticipated pricing strategy for the BREATHE Airway Scaffold upon potential market launch?
How will the enrollment rate and total patient cohort size for BREATHE-3 compare to Apreo's previous trials (BREATHE-1, BREATHE-2)?
What are the potential risks or failure points identified for the BREATHE-3 trial that could impact investor sentiment?
11 days ago